Who Qualifies for GLP-1 Weight Loss Prescriptions in the USA?
BMI thresholds, comorbidities, and the clinical criteria used to determine eligibility.
Not everyone is a candidate for GLP-1 weight-loss therapy, and understanding eligibility criteria helps patients decide whether to pursue an evaluation. This guide reviews the FDA-approved criteria, common clinical considerations, insurance requirements, and situations where GLP-1 therapy is either contraindicated or ill-advised.
FDA-approved criteria for adults
The primary GLP-1 medications approved for chronic weight management in adults are Wegovy (semaglutide) and Zepbound (tirzepatide). Their labels generally cover:
- Adults with a body mass index of 30 kg/m² or higher (obesity), or
- Adults with a BMI of 27 kg/m² or higher (overweight) plus at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
These thresholds are the baseline used by most clinicians and insurers.
Adolescent eligibility
Wegovy is FDA-approved for adolescents ages 12 and older with obesity as defined by CDC growth charts. Zepbound's approval currently applies to adults. Prescribing for younger patients is typically handled by pediatric obesity specialists and involves careful screening for growth, mental health, and family context.
Special populations and off-label use
Some clinicians consider off-label use for patients who fall slightly outside the labeled BMI thresholds—for example, patients with a BMI of 26 who have significant weight-related joint pain, prediabetes, or elevated cardiovascular risk. Off-label prescribing is legal but should be individualized, well-documented, and paired with informed consent. It also may not be covered by insurance.
Additional indications continue to expand. Semaglutide is now approved for reducing cardiovascular risk in adults with obesity and established heart disease. Tirzepatide has been approved for moderate-to-severe obstructive sleep apnea in adults with obesity. These broader indications open access for patients who may not qualify strictly on weight-loss criteria.
Contraindications: who should not use GLP-1 medications
- Personal or family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to the specific medication.
- Pregnancy or plans to become pregnant during treatment; a washout period before conception is generally recommended.
Situations requiring extra caution
Even when eligibility criteria are met, some situations warrant careful evaluation:
- History of pancreatitis or gallbladder disease.
- Severe gastroparesis or other GI motility disorders.
- Active eating disorder or history of anorexia or bulimia.
- Advanced kidney disease.
- Complex diabetes regimens involving insulin or sulfonylureas.
- Older adults at risk of sarcopenia or falls.
These do not necessarily rule out treatment but call for individualized planning, closer monitoring, and often coordination with specialists.
Insurance-specific eligibility
Even if a patient is clinically eligible, insurance rules add another layer. Common insurer requirements include:
- Documented BMI on file within a recent time window.
- Documentation of comorbid conditions.
- Records of prior weight-loss attempts, such as lifestyle programs.
- Concurrent participation in a nutrition or coaching program.
- Annual reauthorization with proof of continued benefit.
Not meeting insurance criteria does not mean a patient is ineligible for treatment—it means the medication would not be covered under that plan.
Special considerations for older adults
Older patients can benefit from GLP-1 therapy, particularly when weight loss improves mobility, cardiovascular risk, or diabetes control. However, the risk of muscle loss and dehydration is higher, and rapid weight loss can complicate frailty. Slower titration, aggressive protein intake, resistance training, and frequent monitoring are important.
Assessing motivation and readiness
Eligibility is not just clinical—it is also about readiness for a long-term commitment. Patients who understand that treatment may last years, that dose adjustments and side effects are part of the process, and that lifestyle habits still matter tend to succeed more often. Motivational interviewing and shared decision-making with a clinician can help clarify readiness before starting.
What a qualifying evaluation looks like
A thorough eligibility evaluation typically includes:
- Complete medical history and medication review.
- Measured height, weight, and BMI.
- Blood pressure and, when indicated, screening labs.
- Discussion of prior weight-loss attempts.
- Screening for eating disorders and mental health concerns.
- Review of contraindications and family history.
- Informed consent about benefits, risks, and expectations.
If you are unsure whether you qualify, the best next step is a conversation with a licensed clinician who can review your specific situation. Even patients who do not currently qualify for GLP-1 therapy often benefit from a broader obesity medicine consultation that identifies other tools and next steps.
GLP-1 weight loss FAQs
Common questions related to who qualifies for glp-1 weight loss prescriptions in the usa? and GLP-1 therapy in the USA.
What are GLP-1 medications and how do they help with weight loss?
GLP-1 receptor agonists mimic a natural gut hormone that signals fullness to the brain and slows how quickly the stomach empties. In the USA, drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management and typically produce 10–20% body weight loss over a year when combined with lifestyle changes.Who qualifies for a GLP-1 weight loss prescription in the USA?
Adults with a BMI of 30 or higher, or 27+ with a weight-related condition such as type 2 diabetes, hypertension, or sleep apnea, generally qualify. A licensed US healthcare provider must evaluate your medical history, current medications, and contraindications before prescribing.How much does GLP-1 weight loss treatment cost in the United States?
Without insurance, brand-name GLP-1 medications typically cost $900–$1,500 per month. Manufacturer savings cards can lower costs for eligible commercially insured patients. Coverage varies widely: many plans require prior authorization, and Medicare currently has limited coverage for weight-loss indications.Does insurance cover GLP-1 drugs for weight loss?
Coverage depends on your plan. Many commercial insurers cover GLP-1s for type 2 diabetes but restrict or exclude coverage for obesity. When covered for weight loss, prior authorization usually requires documented BMI, prior weight-loss attempts, and comorbidities. Appeals are common and often successful with provider support.What are the most common side effects?
Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are most common, especially during dose escalation. Serious but rare risks include pancreatitis and gallbladder disease. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1s.How long do I need to stay on a GLP-1 medication?
Obesity is treated as a chronic condition. Clinical evidence shows that most patients regain weight after stopping GLP-1s, so long-term use — often years — is typical. Your provider may adjust the dose over time and combine treatment with nutrition, exercise, and behavioral support.Is it safe to get GLP-1 prescriptions through telehealth?
Reputable telehealth platforms with licensed US clinicians, thorough medical reviews, and ongoing follow-up can be safe and convenient. Be cautious of services that prescribe without evaluating your history, use unregulated compounded products, or lack proper pharmacy oversight.Can I lose weight on a GLP-1 without changing my diet or exercise?
You may lose some weight, but outcomes are significantly better — and more sustainable — when medication is paired with adequate protein intake, resistance training, sleep, and stress management. Lifestyle habits also help protect muscle mass and metabolic health during weight loss.